tradingkey.logo
搜尋

Beta Bionics Inc

BBNX
添加自選
16.760USD
+0.060+0.36%
收盤 07/02, 13:00美東報價延遲15分鐘
746.85M總市值
虧損本益比TTM

Beta Bionics Inc

16.760
+0.060+0.36%
查看詳細走勢圖
TradingKey 图表
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.36%

5天

+5.34%

1月

+31.04%

6月

-42.70%

今年開始到現在

-45.00%

1年

+18.53%

關鍵數據
16.710今開
17.060最高
606.89K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
1.36%換手率
16.700昨收
16.175最低
7.57M成交額
虧損本益比靜
2.75市淨率
0.00%股息率 TTM
-20.68%ROA
32.71052週最高
1.01量比
-54.76M淨利潤
44.56M總股本
-1.3659每股盈餘TTM
--Beta
-22.71%ROE
8.80052週最低
5.30%振幅
59.50%毛利率
746.85M總市值
7.39回報/風險
4.62%風險率

TradingKey Beta Bionics Inc股票評分

單位: USD 更新時間: 2026-07-02

操作建議

Beta Bionics Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名40/204位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為19.58。中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Beta Bionics Inc評分

相關信息

行業排名
40 / 204
全市場排名
114 / 4565
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
極度看好

Beta Bionics Inc亮點

亮點風險
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
業績高增長
公司營業收入穩步增長,連續3年增長735.77%
利潤高增長
公司淨利潤處於行業前列,最新年度總收入100.25M美元
估值合理
公司最新PE估值-12.27,處於3年歷史合理位
機構減倉
最新機構持股49.25M股,環比減少4.25%
史蒂文·科恩持倉
明星投資者史蒂文·科恩持倉,最新持倉2.18M股

分析師目標

基於 12 分析師
買入
評級
19.583
目標均價
+15.20%
漲幅空間

Beta Bionics Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Beta Bionics Inc簡介

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
公司代碼BBNX
公司Beta Bionics Inc
CEOSaint (Sean)
網址https://www.betabionics.com

常見問題

Beta Bionics Inc(BBNX)的當前股價是多少?

Beta Bionics Inc(BBNX)的當前股價是 16.76。

Beta Bionics Inc 的股票代碼是什麼?

Beta Bionics Inc的股票代碼是BBNX。

Beta Bionics Inc股票的52週最高點是多少?

Beta Bionics Inc股票的52週最高點是32.71。

Beta Bionics Inc股票的52週最低點是多少?

Beta Bionics Inc股票的52週最低點是8.80。

Beta Bionics Inc的市值是多少?

Beta Bionics Inc的市值是746.85M。

現在Beta Bionics Inc(BBNX)的股票是買入、持有還是賣出?

根據分析師評級,Beta Bionics Inc(BBNX)的總體評級為買入,目標價格為19.58。

Beta Bionics Inc(BBNX)股票的每股收益(EPS TTM)是多少

Beta Bionics Inc(BBNX)股票的每股收益(EPS TTM)是-1.81。